Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | PGK1 | P00558 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220430 | 0.88 | PGK1 (0.44) | KMT2AKDM4EPGK1ALDH1A1GAA | |
| SCHEMBL5860177 | 0.82 | MAPT (0.44) | KMT2AKDM4EPGK1ALDH1A1GAA | |
| SCHEMBL7972875 | 0.82 | KMT2A (0.47) | KMT2AKDM4EPGK1HTTALDH1A1 | |
| SCHEMBL5860061 | 0.81 | PGK1 (0.46) | KMT2APGK1GAAMAPTSMN1; SMN2 | |
| SCHEMBL7986686 | 0.73 | MAPT (0.41) | KMT2AKDM4EPGK1ALDH1A1GAA | |
| SCHEMBL5862678 | 0.73 | GABRA1 (0.41) | KMT2AALDH1A1GAAMAPTTSHR | |
| SCHEMBL5862670 | 0.72 | TNF (0.39) | KMT2AKDM4EALDH1A1GAAMAPT | |
| SCHEMBL20504510 | 0.72 | EHMT2 (0.52) | — | |
| SCHEMBL5859933 | 0.71 | KDM4E (0.43) | KDM4EALDH1A1MAPTTSHRTDP1 | |
| SCHEMBL14492309 | 0.69 | MAPT (0.49) | KDM4EALDH1A1GAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135478-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-11-14 | — | — | US | disclosed |
| US-7053102-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-05-30 | — | — | US | disclosed |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2005-02-17 | — | — | US | disclosed |
| US-20040254163-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2004-12-16 | — | — | US | disclosed |
| US-6815546-B2 | ANTICANCER AGENTS | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-11-09 | — | — | US | disclosed |
| US-6797715-B1 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-09-28 | — | — | US | disclosed |
| US-6762301-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-13 | — | — | US | disclosed |
| US-20030004150-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2003-01-02 | — | — | US | disclosed |
| US-20020160994-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2002-10-31 | — | — | US | disclosed |
| US-6339091-B1 | USEFUL IN THERAPY OF OF VIRAL INFECTIONS, PARASITIC DISEASES AND CANCER | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254163-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP2A, TOP1, MCL1 | KMT2A 4109/4885KDM4E 4381/4885PGK1 1665/4885 |
| US-20030004150-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP1, TOP2A, TYMP | KMT2A 4064/4885KDM4E 4443/4885PGK1 1283/4885 |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | MCL1, BRCA1, API5 | KMT2A 1052/4885KDM4E 699/4885PGK1 2732/4885 |
| US-20020160994-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP2A, TOP1, TOP2B | KMT2A 3127/4885KDM4E 4167/4885PGK1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.